Lupin reported quarter I, FY2019 financial results

Pharma major Lupin Limited reported its financial performance for the first quarter ending June 30, 2018. Sales for the quarter were Rs. 37,746 million compared to Rs. 39,785 million in Q4 FY2018 and Rs. 38,068 million in Q1 FY2018. Earnings before interest, tax, depreciation, and amortization (EBITDA) for the quarter were Rs. 7112 million compared to Rs. 8536 million in Q4 FY2018 and Rs. 8003 million in Q1 FY2018. Net profits before exceptional items for the quarter were Rs. 2028 million compared to Rs. 3586 million in Q4 FY2018 and Rs. 3581 million in Q1 FY2018. Investment in research for the quarter was Rs. 3753 million, representing 9.9 percent of sales.

“The first quarter of FY2019 has been subdued, primarily on account of the US and Japan. We remain committed to accelerating new product introductions, evolving our business, and delivering on operational and cost efficiencies.”

Nilesh Gupta
Managing Director,
Lupin Limited